We have located links that may give you full text access.
Evaluation of the Mayo Additive Staging System in patients with newly diagnosed multiple myeloma: A real-world analysis.
European Journal of Haematology 2022 November 12
OBJECTIVES: Recently, the Mayo Clinic introduced a new staging system (the Mayo Additive Staging System, MASS) for patients with newly diagnosed multiple myeloma (NDMM) based on the number of high-risk (HR) abnormalities, including HR IgH translocations, 1q gain/amplification, chromosome 17 abnormalities, ISS-III, and elevated LDH. Patients with 0, 1, or ≥2 HR abnormalities were defined as stage I, II, or III, respectively. We aimed to validate the real-world prognostic value of the MASS.
METHODS: We retrospectively analyzed the cytogenetic and laboratory results of 544 patients with NDMM at a single center.
RESULTS: Ninety (16.5%) patients had no HR factors (MASS I), 193 (35.5%) had 1 high-risk factor (MASS II) and 261 (48%) had ≥2 high-risk factors (MASS III). The median PFS and OS times were 48, 28 and 20 months and 137, 73 and 39 months in the 3 groups, respectively (P < 0.001). In the subgroup analysis, patients had different OS outcomes based on the MASS when grouped by age, renal function or therapeutic regimens. The MASS identified patients with the worst outcomes among those rated R-ISS II.
CONCLUSION: The MASS system is a reliable risk stratification tool for patients with NDMM in real-world clinical practice. This article is protected by copyright. All rights reserved.
METHODS: We retrospectively analyzed the cytogenetic and laboratory results of 544 patients with NDMM at a single center.
RESULTS: Ninety (16.5%) patients had no HR factors (MASS I), 193 (35.5%) had 1 high-risk factor (MASS II) and 261 (48%) had ≥2 high-risk factors (MASS III). The median PFS and OS times were 48, 28 and 20 months and 137, 73 and 39 months in the 3 groups, respectively (P < 0.001). In the subgroup analysis, patients had different OS outcomes based on the MASS when grouped by age, renal function or therapeutic regimens. The MASS identified patients with the worst outcomes among those rated R-ISS II.
CONCLUSION: The MASS system is a reliable risk stratification tool for patients with NDMM in real-world clinical practice. This article is protected by copyright. All rights reserved.
Full text links
Related Resources
Trending Papers
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app